BeiGene, Ltd. Stock price

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
156.4 USD +0.84% Intraday chart for BeiGene, Ltd. -4.47% -13.29%
Sales 2024 * 3.08B Sales 2025 * 3.93B Capitalization 16.33B
Net income 2024 * -874M Net income 2025 * -350M EV / Sales 2024 * 4.79 x
Net cash position 2024 * 1.58B Net cash position 2025 * 1.18B EV / Sales 2025 * 3.86 x
P/E ratio 2024 *
-18.3 x
P/E ratio 2025 *
-48.9 x
Employees 10,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.21%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.84%
1 week-7.80%
Current month-5.59%
1 month-12.97%
3 months-12.60%
6 months-18.62%
Current year-13.29%
More quotes
1 week
151.49
Extreme 151.49
158.10
1 month
151.49
Extreme 151.49
184.80
Current year
132.95
Extreme 132.95
184.80
1 year
132.95
Extreme 132.95
272.49
3 years
118.18
Extreme 118.18
426.56
5 years
113.01
Extreme 113.01
426.56
10 years
22.51
Extreme 22.51
426.56
More quotes
Date Price Change Volume
24-03-28 156.4 +0.84% 104,129
24-03-27 155.1 +0.83% 76,134
24-03-26 153.8 -0.07% 104,417
24-03-25 153.9 +1.25% 122,678
24-03-22 152 -7.14% 445,487

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
156.4 USD
Average target price
269.4 USD
Spread / Average Target
+72.23%
Consensus
  1. Stock
  2. Equities
  3. Stock BeiGene, Ltd. - Nasdaq